Clinical Trial Update: Thalidomide in Treating Patients With Refractory or Resistant Epithelial Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update on thalidomide for patients with refractory or resistant epithelial ovarian cancer. The trial status is COMPLETED.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Ovarian Cancer

Drugs mentioned

• Thalidomide (thalidomide)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED